NOS2 and renal carcinoma: Targeting of effector functions can be achieved via inhibition of phosphodiesterase, reducing expression of Arg1 and iNOS (123, 124), similar to the HDAC inhibitor entinostat, which reduces expression of COX2, Arg1, and NOS2 in mouse models of melanoma and renal carcinoma (125).